GlaxoSmithKline (GSK) Posts Q3 Results, Lifts Outlook

GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.47, versus the analyst estimate of GBP0.93. Revenue for the quarter came in at GBP7.8 billion versus the consensus estimate of GBP8.24 billion.

GUIDANCE:

2022 Guidance raised: expect to deliver growth in sales of between 8% to 10% CER and growth in 2022 adjusted operating profit of between 15% to 17% CER.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform